Myeloma Patient Preferences and Perspectives on Intravenous (IV) and Subcutaneous (SC) Myeloma Therapies
About
This survey seeks to understand your preferences between subcutaneous (SC) and intravenous (IV) bispecific therapies for multiple myeloma to improve future treatment options.
25 minutes
Dr. Larry D. Anderson Jr., M.D., Ph.D., FACP, a Professor in the Department of Internal Medicine at UT Southwestern Medical Center and Director of the Myeloma, Waldenström's, and Amyloidosis Program.
Contact Information
For any questions or concerns regarding the study, participants can contact HealthTree Patient Navigators at support@healthtree.org.